438 related articles for article (PubMed ID: 19378901)
1. Management of central diabetes insipidus with oral desmopressin in a patient with ectrodactyly and cleft lip/palate (ECP) syndrome.
Ozaydin E; Aycan Z; Yusufoğlu AM; Cetinkaya E; Ergen S; Unal S; Köse G
Turk J Pediatr; 2009; 51(1):89-93. PubMed ID: 19378901
[TBL] [Abstract][Full Text] [Related]
2. [Persistent central diabetes insipidus in a very low birth weight infant].
Quetin F; Garnier H; Brauner R; Vodovar M; Magny JF
Arch Pediatr; 2007 Nov; 14(11):1321-3. PubMed ID: 17916426
[TBL] [Abstract][Full Text] [Related]
3. Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations.
Kim RJ; Malattia C; Allen M; Moshang T; Maghnie M
Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():115-23. PubMed ID: 16456490
[TBL] [Abstract][Full Text] [Related]
4. Management of central diabetes insipidus with oral desmopressin lyophilisate in infants.
Korkmaz HA; Demir K; Kılıç FK; Terek D; Arslanoğlu S; Dizdarer C; Ozkan B
J Pediatr Endocrinol Metab; 2014 Sep; 27(9-10):923-7. PubMed ID: 24854529
[TBL] [Abstract][Full Text] [Related]
5. Use of desmopressin eye drops in the treatment of equine congenital central diabetes insipidus.
Kranenburg LC; Thelen MH; Westermann CM; de Graaf-Roelfsema E; van der Kolk JH
Vet Rec; 2010 Nov; 167(20):790-1. PubMed ID: 21262613
[No Abstract] [Full Text] [Related]
6. Variability in Oral Desmopressin Dose Requirements in Children with Central Diabetes Insipidus.
Almutlaq N; Eugster EA
J Pediatr; 2021 Dec; 239():228-230. PubMed ID: 34487771
[TBL] [Abstract][Full Text] [Related]
7. Intravenous formulation of desmopressin delivered via oral and g tube routes for the treatment of central diabetes insipidus: First experience in infants.
Lim WY; Riba-Wolman R
Clin Endocrinol (Oxf); 2020 Feb; 92(2):179-181. PubMed ID: 31715009
[No Abstract] [Full Text] [Related]
8. Profound hypernatremia due to central diabetes insipidus.
Vaqar A; Rafiq A; Javaid KH; Parveen R; Sadaf R
J Coll Physicians Surg Pak; 2012 Jun; 22(6):409-11. PubMed ID: 22630107
[TBL] [Abstract][Full Text] [Related]
9. [Treatment with sublingual desmopressin in two infants with hydranencephaly and central diabetes insipidus].
Marín GR; Baspineiro B; Vilca I
Arch Argent Pediatr; 2018 Feb; 116(1):e93-e97. PubMed ID: 29333830
[TBL] [Abstract][Full Text] [Related]
10. Buccally Administered Intranasal Desmopressin Acetate for the Treatment of Neurogenic Diabetes Insipidus in Infancy.
Smego AR; Backeljauw P; Gutmark-Little I
J Clin Endocrinol Metab; 2016 May; 101(5):2084-8. PubMed ID: 27011115
[TBL] [Abstract][Full Text] [Related]
11. [Dysmaturity as symptom of the ectrodactyly-ectodermal dysplasia-clefting (EEC) syndrome].
Porcelijn L; Maat-Kievit JA; van Haeringen A
Tijdschr Kindergeneeskd; 1993 Jun; 61(3):96-9. PubMed ID: 8211943
[TBL] [Abstract][Full Text] [Related]
12. Central diabetes insipidus in five cats: clinical presentation, diagnosis and oral desmopressin therapy.
Aroch I; Mazaki-Tovi M; Shemesh O; Sarfaty H; Segev G
J Feline Med Surg; 2005 Dec; 7(6):333-9. PubMed ID: 15927500
[TBL] [Abstract][Full Text] [Related]
13. Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus.
Kataoka Y; Nishida S; Hirakawa A; Oiso Y; Arima H
Endocr J; 2015; 62(2):195-200. PubMed ID: 25382102
[TBL] [Abstract][Full Text] [Related]
14. Ectodermal dysplasia, ectrodactyly, cleft lip/palate syndrome without ectrodactyly.
Sankhyan N; Kaushal RK; Sarin S
Dermatol Online J; 2006 May; 12(4):5. PubMed ID: 17083860
[TBL] [Abstract][Full Text] [Related]
15. Comments on "Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study"--efficacy and safety of orally disintegrating desmopressin tablets in patients with central diabetes insipidus.
Kamoi K
Endocr J; 2013; 60(9):1115. PubMed ID: 23863202
[No Abstract] [Full Text] [Related]
16. Trauma-induced central diabetes insipidus in a cat.
Campbell FE; Bredhauer B
Aust Vet J; 2008 Mar; 86(3):102-5. PubMed ID: 18304048
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study.
Arima H; Oiso Y; Juul KV; Nørgaard JP
Endocr J; 2013; 60(9):1085-94. PubMed ID: 23811987
[TBL] [Abstract][Full Text] [Related]
18. Oral desmopressin in neonatal diabetes insipidus.
Stick SM; Betts PR
Arch Dis Child; 1987 Nov; 62(11):1177-8. PubMed ID: 3688926
[TBL] [Abstract][Full Text] [Related]
19. National Surveillance of Central Diabetes Insipidus (CDI) in Denmark: results from 5 years registration of 9309 prescriptions of desmopressin to 1285 CDI patients.
Juul KV; Schroeder M; Rittig S; Nørgaard JP
J Clin Endocrinol Metab; 2014 Jun; 99(6):2181-7. PubMed ID: 24527719
[TBL] [Abstract][Full Text] [Related]
20. A patient with essential hypernatremia had good response to desmopressin acetate therapy.
Guo Q; Lu J; Mu Y; Dou J; Pan C
Neuro Endocrinol Lett; 2010; 31(5):588-93. PubMed ID: 21173753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
